Canada’s #1 Premium Weed Brand Rubicon Makes a Big Bet
In today’s Trade To Black podcast presented by Flowhub, Shadd Dales and Anthony Varrell welcome back Rubicon Organics (TSXV: ROMJ) CEO Margaret Brodie to break down the company’s fresh $3 million raise. Then we dig into this week’s NuggMD Check-In Poll on whether cannabis products live up to their labeled potency.
The non-brokered private placement comes from strategic investor Siwash Rock Investments: 6,666,667 shares at $0.45, with no warrants or finder’s fees. The money funds a lighting upgrade at Pacifica, Rubicon’s 125,000-square-foot greenhouse in Delta, B.C. Management expects the upgrade to lift Pacifica’s output about 40% to roughly 15,500 kilograms a year. It should also pull Rubicon’s path to about 20,000 kilograms by June 2027 forward by about a year, with no new building or licence. Brodie says Pacifica has already increased yield about 20% this year. Cascadia, acquired last year, is producing strong quality but hasn’t yet hit its yield targets.
Brodie says demand has outstripped Rubicon’s supply for years. The extra flower will go into large-format bags, which the Ontario Cannabis Store has only been able to carry as supply allows, and into international markets. Rubicon has signed four international contracts and still expects international sales to reach about 10% of 2026 revenue. Domestically, she says pre-rolls continue to surge as consumers favour convenience. Rubicon is also moving its award-winning Pink Drip strain to its 1964 brand.
Brodie welcomes Ontario’s new enforcement powers against unlicensed storefronts and online sellers. She says the federal government is finally reaching out to support the industry, and she wants it to start by fixing the excise tax.
On growing talk of U.S. multi-state operators eyeing Canadian licensed producers, Brodie says consistent supply will be the deciding factor. Rubicon was Canada’s top premium licensed producer in Q2 2026, with 6.8% of the premium segment and record quarterly revenue of $18.5 million, in a category where Brodie expects only two to four super-premium brands to survive.
This week’s NuggMD poll surveyed 654 cannabis consumers. Seventy percent said a product’s effects were stronger or weaker than its labeled potency suggested, including 42% who had experienced both. Only 26% said never. Varrell argues that consumption method, terpene profile and genetics shape the experience more than the THC number on the label. The hosts also look at what the results mean for tolerance and consumer trust.
A second NuggMD survey shows consumer approval of the administration’s cannabis actions falling to 29%, down from 48% last quarter and 73% the quarter before.
Tune in for the full conversation.
